Proteome Sciences (GB:PRM) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Proteome Sciences PLC has reported a surge in customer engagement and service inquiries in 2024, including a significant contract from a US biopharmaceutical company. The firm is optimistic about returning to growth this year, bolstered by the launch of new proteomics services and expansion in the US. Proteome Sciences specializes in proteomics services for drug discovery and biomarker identification, with proprietary technologies like SysQuant® and TMT®MS2.
For further insights into GB:PRM stock, check out TipRanks’ Stock Analysis page.
